(3R,4S,5R,6R)-3,4,5-tris(triMethylsilyloxy)-6-((triMethylsilyloxy)Methyl)tetrahydro-2H-pyran-2-one CAS NO.32384-65-9

Canagliflozin (1), jointly developed by Mitsubishi and Johnson & Johnson, was approved by FDA on March 29, 2013. It is the first sodium glucose cotransporter 2 (SGLT2) inhibitor approved by FDA. The drug was approved by the European Commission (EC) on November 25, 2013 for the treatment of type 2 diabetes in adults.

By inhibiting SGLT2, the glucose in renal tubules can not be reabsorbed into the blood and excreted with urine, thus reducing the blood glucose concentration.

2,3,4,6-tetra-o-trimethylsilyl-d-glucosyl-1,5-lactone is an antidiabetic drug and an intermediate of dagliejing.

2,3,4,6-tetra-o-trimethylsilyl-d-glucosyl-1,5-lactone was used as a reagent for the synthesis of C-glucose containing trans cyclohexane and as a sodium glucose cotransporter 2 inhibitor.

COMPANY INTRODUCTION

JIN DUN CHEMICAL belongs to JIN DUN GROUP. It is a professional enterprise dedicated to the development and production of special (meth)acrylate monomers. The head office is located in Shanghai city, near Hongqiao airport.The R&D center of JIN DUN is located in Ningbo city, Zhejiang province.  

JIN DUN CHEMICAL focus on the coating, automobile, electricity and pharmaceutical area, always try best to be the professional supplier of new raw material for the advanced material in coating, automobile chemicals, electricity chemicals and pharmaceutical intermediate.

The EU company of JIN DUN CHEMICAL located at Frankfurt in Germany. It makes us service our customer better in EU, but also takes more valued information for our creation and future developing.

Welcome our customers and friends to visit our company.